These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 26924734)
1. 4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery. Kim CH; Leblanc P; Kim KS Expert Opin Drug Discov; 2016; 11(4):337-41. PubMed ID: 26924734 [No Abstract] [Full Text] [Related]
2. Rational drug discovery design approaches for treating Parkinson's disease. Van der Schyf CJ Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694 [TBL] [Abstract][Full Text] [Related]
3. Researchers unite to improve Parkinson's drug discovery. Dolgin E Nat Med; 2010 Mar; 16(3):247. PubMed ID: 20208492 [No Abstract] [Full Text] [Related]
4. Recent progress in drug discovery for Parkinson's disease. Gilligan PJ Curr Top Med Chem; 2015; 15(10):905-7. PubMed ID: 25832717 [No Abstract] [Full Text] [Related]
8. [Recent acquisitions in therapy of Parkinson's disease]. Casacchia M; Cappellini R; Meco G Clin Ter; 1981 Nov; 99(4):401-11. PubMed ID: 7030592 [No Abstract] [Full Text] [Related]
9. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. Shah U; Hodgson R Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030 [TBL] [Abstract][Full Text] [Related]
10. Novel models for Parkinson's disease and their impact on future drug discovery. Trigo-Damas I; Del Rey NL; Blesa J Expert Opin Drug Discov; 2018 Mar; 13(3):229-239. PubMed ID: 29363335 [TBL] [Abstract][Full Text] [Related]
11. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related]
12. Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136 [No Abstract] [Full Text] [Related]
13. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa]. Broussolle E Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845 [No Abstract] [Full Text] [Related]
14. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
15. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Xie T; Ho SL; Ramsden D Lancet; 1998 Jun; 351(9120):1966. PubMed ID: 9654300 [No Abstract] [Full Text] [Related]
16. Parkinson's disease. Drug treatment in old age. Derbyshire M; Marsden V Elder Care; 1999 Apr; 11(2):31-4. PubMed ID: 10542523 [No Abstract] [Full Text] [Related]
17. ABCB1: is there a role in the drug treatment of Parkinson's disease? Müller T Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):127-129. PubMed ID: 29224383 [No Abstract] [Full Text] [Related]
19. Darkening of white hair following levodopa therapy in a patient with Parkinson's disease. Komagamine T; Suzuki K; Hirata K Mov Disord; 2013 Oct; 28(12):1643. PubMed ID: 24166898 [No Abstract] [Full Text] [Related]
20. Motor fluctuations in Parkinson's disease. Crabb L Prof Nurse; 2000 Jan; 15(4):273-7. PubMed ID: 10983145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]